Aug 9 (Reuters) - Anthera Pharmaceuticals Inc :Anthera Pharmaceuticals provides business update and reports 2017 second quarter financial results.Q2 earnings per share $0.03.Anthera Pharmaceuticals Inc - bright, phase 2 study of blisibimod in iga nephropathy remains on track to report topline data in Q3.Anthera Pharmaceuticals Inc - ended Q2 of 2017 with cash and cash equivalents totaling $11.2 million, compared to $20.8 million as of December 31, 2016.
Aug 9 (Reuters) - Progenics Pharmaceuticals Inc :Progenics Pharmaceuticals announces second quarter 2017 financial results and business update.Q2 loss per share $0.24.Q2 earnings per share view $-0.21 -- Thomson Reuters I/B/E/S.Progenics Pharmaceuticals Inc - qtrly total revenues $2.8 million versus $8.5 million.Azedra NDA expected to be submitted August 2017.Q2 revenue view $3.7 million -- Thomson Reuters I/B/E/S.
Aug 9 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports 2017 second quarter financial results and provides business update.Q2 loss per share $0.15.Q2 earnings per share view $-0.19 -- Thomson Reuters I/B/E/S.Corbus Pharmaceuticals Holdings Inc - ended Q2 with approximately $43.0 million of cash and cash equivalents.
Aug 8 (Reuters) - Esperion Therapeutics Inc ::Esperion announces proposed public offering of common stock.Says intends to offer and sell $150 million of its common stock in an underwritten public offering.Esperion Therapeutics - to use net proceeds from offering, other existing capital resources, to fund clear outcomes cardiovascular outcomes trial.
Aug 8 (Reuters) - Cellular Biomedicine Group Inc ::Cellular Biomedicine Group reports second quarter and first half 2017 financial results and business highlights.Cellular Biomedicine Group Inc - cash and cash equivalents as of June 30, 2017 were $27.3 million compared to $39.3 million as of December 31, 2016.Cellular Biomedicine Group Inc qtrly loss per share $0.43.
Aug 8 (Reuters) - Dynavax Technologies Corp :Dynavax announces proposed public offering of common stock.Dynavax Technologies Corp - intends to offer and sell $125.0 million of shares of its common stock.Dynavax-Sees using proceeds from proposed offering to fund activities associated with preparing for anticipated U.S. Commercial launch of Heplisav-B.
Aug 8 (Reuters) - OpGen Inc :OpGen reports 2017 second quarter financial results and provides business update.Q2 revenue $700,000 versus $1.2 million.OpGen Inc qtrly net loss per common share, basic and diluted, $0.15.OpGen - first of rapid tests expected to be tested at third-party clinical evaluation sites in q4 and launched as an ruo test in first half of 2018.OpGen Inc - cash and cash equivalents were $0.2 million as of June 30, 2017 compared with $4.1 million as of december 31, 2016.OpGen Inc - expect a decrease in operating expenses of approximately 25% to 30% in second half of 2017.
Aug 8 (Reuters) - Endocyte Inc :Endocyte reports second quarter financial results and provides clinical and pipeline update.Q2 loss per share $0.28.Endocyte - plans to initiate clinical development for Car T-Cell program in osteosarcoma in 2018; IND filed for dual-targeted DNA crosslinker EC2629.Endocyte - sees cash, cash equivalents balance at end of 2017 about $105 million; full expense impact of restructuring expected to be realized by end of Q4.
Aug 4 (Reuters) - Digiliti Money Group Inc :Digiliti money announces preliminary second quarter 2017 results.Sees q2 revenue $1.1 million to $1.3 million."our topline for quarter was lower than expected".Digiliti money group inc says digiliti money expects to seek financing to support its operations going forward.Digiliti money group inc says also expects an accounts receivable reserve in amount of $1.8 million, due to unilateral noncontractual termination in q2.Digiliti money group inc - in process of implementing several cost-cutting initiatives.Digiliti money - expect cost-cutting initiatives on fy, continuing basis, to reduce annual operating expenses by nearly $3 million when fully implemented.Digiliti money-if co is not able to achieve financing, sufficient positive cash flow from operations, it may not be able to continue as going concern.
Aug 3 (Reuters) - Minerva Neurosciences Inc :Minerva Neurosciences reports second quarter 2017 financial results and business updates.Q2 loss per share $0.27.Minerva Neurosciences Inc - cash, cash equivalents and marketable securities as of June 30 were about $77.6 million, versus $83.0 million as of Dec 31, 2016.Minerva Neurosciences Inc - phase 2B clinical trial with MIN-117 in MDD is planned for initiation in late 2017.